Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS) A Prospective Randomized Open-label Blinded Endpoint (PROBE) Multicenter Non-inferiority Study

NCT04121403 is registered in ClinicalTrials.gov with Oslo University Hospital as lead sponsor.

NCT NCT04121403
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04121403 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS) A Prospective Randomized Open-label Blinded Endpoint (PROBE) Multicenter Non-inferiority Study
Lead sponsor
Oslo University Hospital
Phase
Phase 3
Overall status
Completed
Start date
October 16, 2019
Completion date
August 31, 2024
Enrollment
267 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis, relapsing multiple sclerosis